US6747003B1
(en)
|
1997-10-23 |
2004-06-08 |
Regents Of The University Of Minnesota |
Modified vitamin K-dependent polypeptides
|
US7247708B2
(en)
|
1997-10-23 |
2007-07-24 |
Regents Of The University Of Minnesota |
Modified vitamin K-dependent polypeptides
|
RU2278123C2
(ru)
|
2000-02-11 |
2006-06-20 |
Максиджен Холдингз Лтд. |
Молекулы, подобные фактору vii или viia
|
US7220837B1
(en)
|
2000-04-28 |
2007-05-22 |
Regents Of The University Of Minnesota |
Modified vitamin K-dependent polypeptides
|
US7812132B2
(en)
|
2000-04-28 |
2010-10-12 |
Regents Of The University Of Minnesota |
Modified vitamin K-dependent polypeptides
|
US6905683B2
(en)
|
2000-05-03 |
2005-06-14 |
Novo Nordisk Healthcare A/G |
Human coagulation factor VII variants
|
US20030211094A1
(en)
|
2001-06-26 |
2003-11-13 |
Nelsestuen Gary L. |
High molecular weight derivatives of vitamin k-dependent polypeptides
|
JP4361728B2
(ja)
*
|
2000-09-13 |
2009-11-11 |
ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト |
ヒト凝固因子vii変異型
|
CA2420892A1
(en)
|
2000-09-13 |
2002-03-21 |
Novo Nordisk A/S |
Human coagulation factor vii variants
|
AU2002218029A1
(en)
|
2000-11-09 |
2002-05-21 |
The Scripps Research Institute |
Modified factor viia
|
US7235638B2
(en)
|
2001-03-22 |
2007-06-26 |
Novo Nordisk Healthcare A/G |
Coagulation factor VII derivatives
|
ES2376694T3
(es)
*
|
2001-09-27 |
2012-03-16 |
Novo Nordisk Health Care Ag |
Polipã‰ptidos del factor vii de coagulaciã“n humano.
|
US7052868B2
(en)
|
2001-09-27 |
2006-05-30 |
Novo Nordisk Healthcare A/G |
Human coagulation factor VII polypeptides
|
US7173003B2
(en)
|
2001-10-10 |
2007-02-06 |
Neose Technologies, Inc. |
Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
|
US7157277B2
(en)
|
2001-11-28 |
2007-01-02 |
Neose Technologies, Inc. |
Factor VIII remodeling and glycoconjugation of Factor VIII
|
US7214660B2
(en)
|
2001-10-10 |
2007-05-08 |
Neose Technologies, Inc. |
Erythropoietin: remodeling and glycoconjugation of erythropoietin
|
ES2490590T3
(es)
*
|
2001-11-02 |
2014-09-04 |
Novo Nordisk Health Care Ag |
Polipéptidos de factor VII de coagulación humana
|
US6960657B2
(en)
|
2001-11-02 |
2005-11-01 |
Novo Nordisk Healthcare A/G |
Human coagulation factor VII polypeptides
|
JP2005508985A
(ja)
*
|
2001-11-09 |
2005-04-07 |
ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト |
Vii因子ポリペプチドおよびアプロチニンポリペプチドを含む薬学的組成物
|
JP2005510515A
(ja)
*
|
2001-11-09 |
2005-04-21 |
ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト |
Vii因子ポリペプチドおよびプロテインc阻害剤を含む薬学的組成物
|
CA2464614A1
(en)
*
|
2001-11-09 |
2003-05-15 |
Novo Nordisk Health Care Ag |
Pharmaceutical composition comprising factor vii polypeptides and pai-1 polypeptides
|
US7291587B2
(en)
|
2001-11-09 |
2007-11-06 |
Novo Nordisk Healthcare A/G |
Pharmaceutical composition comprising factor VII polypeptides and TAFI polypeptides
|
EP1446153A1
(de)
*
|
2001-11-09 |
2004-08-18 |
Novo Nordisk Health Care AG |
Pharmazeutische zusammensetzung mit faktor-vii- polypeptiden und gewebeplasminogen-inhibitoren
|
US7078479B2
(en)
|
2001-11-09 |
2006-07-18 |
Novo Nordisk Healthcare A/G |
Pharmaceutical composition comprising factor VII polypeptides and alpha2-antiplasmin polypeptides
|
JP2005515175A
(ja)
*
|
2001-11-09 |
2005-05-26 |
ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト |
第vii因子ポリペプチドおよびアルファ2−抗プラスミンポリペプチドを含む薬学的組成物
|
WO2003039579A1
(en)
*
|
2001-11-09 |
2003-05-15 |
Novo Nordisk Health Care Ag |
Pharmaceutical composition comprising factor vii polypeptides and tafi polypeptides
|
HUP0402315A3
(en)
|
2001-12-21 |
2009-03-30 |
Novo Nordisk Healthcare Ag |
Liquid composition of factor vii polypeptides
|
US7700733B2
(en)
|
2002-04-30 |
2010-04-20 |
Bayer Healthcare Llc |
Factor VII or VIIa polypeptide variants
|
CN1671410B
(zh)
|
2002-06-21 |
2010-05-12 |
诺和诺德医疗保健公司 |
因子ⅶ多肽的稳定化固体组合物
|
PT1517710E
(pt)
|
2002-06-21 |
2011-07-08 |
Novo Nordisk Healthcare Ag |
Glicoformas do factor vii peguilado
|
US6933136B2
(en)
|
2002-09-20 |
2005-08-23 |
Novo Nordisk A/S |
Method for making recombinant proteins
|
US6911323B2
(en)
|
2002-09-25 |
2005-06-28 |
Novo Nordisk Healthcare A/G |
Human coagulation factor VII polypeptides
|
DE60315847T2
(de)
|
2002-09-25 |
2008-05-15 |
Novo Nordisk Health Care Ag |
Varianten des menschliche koagulationsfaktors vii
|
EP3103869A1
(de)
|
2003-03-18 |
2016-12-14 |
Novo Nordisk Health Care AG |
Verfahren zur herstellung von factor vii polypeptiden
|
ES2327044T3
(es)
|
2003-03-20 |
2009-10-23 |
Bayer Healthcare Llc |
Variantes de fvii o fviia.
|
EP1615945B1
(de)
|
2003-04-09 |
2011-09-28 |
BioGeneriX AG |
Glycopegylierungsverfahren und durch die verfahren hergestellte proteine/peptide
|
US8791070B2
(en)
|
2003-04-09 |
2014-07-29 |
Novo Nordisk A/S |
Glycopegylated factor IX
|
NZ544728A
(en)
|
2003-06-19 |
2009-04-30 |
Bayer Healthcare Llc |
Factor VII or VIIa Gla domain variants
|
ES2382157T3
(es)
*
|
2003-06-25 |
2012-06-05 |
Novo Nordisk Health Care Ag |
Composición líquida de polipépttidos del factor VII
|
US9005625B2
(en)
|
2003-07-25 |
2015-04-14 |
Novo Nordisk A/S |
Antibody toxin conjugates
|
ES2381110T3
(es)
*
|
2003-09-09 |
2012-05-23 |
Novo Nordisk Health Care Ag |
Polipéptidos de factor VII de coagulación
|
WO2005032581A2
(en)
|
2003-10-07 |
2005-04-14 |
Novo Nordisk Health Care Ag |
Hybrid molecules having factor vii/viia activity
|
US20080305992A1
(en)
|
2003-11-24 |
2008-12-11 |
Neose Technologies, Inc. |
Glycopegylated erythropoietin
|
EP1711513B1
(de)
|
2003-12-01 |
2014-07-02 |
Novo Nordisk Health Care AG |
Nanofiltration von faktor vii lösungen zur entfernung von viren
|
US20060040856A1
(en)
|
2003-12-03 |
2006-02-23 |
Neose Technologies, Inc. |
Glycopegylated factor IX
|
EP3378470A1
(de)
|
2003-12-19 |
2018-09-26 |
Novo Nordisk Health Care AG |
Stabilisierte zusammensetzungen aus faktor-vii-polypeptiden
|
ATE550041T1
(de)
|
2004-01-21 |
2012-04-15 |
Novo Nordisk Healthcare Ag |
Transglutaminase-vermittelte konjugation von peptiden
|
WO2005075635A2
(en)
*
|
2004-02-03 |
2005-08-18 |
Novo Nordisk Health Care Ag |
Coagulation factor vii/viia variants lacking a functional lipid membrane binding domain
|
US20080176790A1
(en)
|
2004-10-29 |
2008-07-24 |
Defrees Shawn |
Remodeling and Glycopegylation of Fibroblast Growth Factor (Fgf)
|
PL1831242T3
(pl)
|
2004-12-23 |
2013-04-30 |
Novo Nordisk Healthcare Ag |
Zmniejszanie zawartości zanieczyszczeń białkowych w kompozycjach zawierających zależne od witaminy K białko będące przedmiotem zainteresowania
|
US9029331B2
(en)
|
2005-01-10 |
2015-05-12 |
Novo Nordisk A/S |
Glycopegylated granulocyte colony stimulating factor
|
US20070154992A1
(en)
|
2005-04-08 |
2007-07-05 |
Neose Technologies, Inc. |
Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
|
JP5216580B2
(ja)
|
2005-05-25 |
2013-06-19 |
ノヴォ ノルディスク アー/エス |
グリコペグ化第ix因子
|
EP1893632B1
(de)
|
2005-06-17 |
2015-08-12 |
Novo Nordisk Health Care AG |
Selektive reduktion und derivatisierung manipulierter faktor vii proteine mit mindestens einem nichtnativen zystein
|
WO2007006808A1
(en)
|
2005-07-13 |
2007-01-18 |
Novo Nordisk Health Care Ag |
Host cell protein knock-out cells for production of therapeutic proteins
|
US20070105755A1
(en)
|
2005-10-26 |
2007-05-10 |
Neose Technologies, Inc. |
One pot desialylation and glycopegylation of therapeutic peptides
|
CN101268185B
(zh)
|
2005-09-01 |
2013-03-27 |
诺沃-诺迪斯克保健股份有限公司 |
因子ⅶ多肽的疏水作用色谱纯化
|
WO2007031559A2
(en)
|
2005-09-14 |
2007-03-22 |
Novo Nordisk Health Care Ag |
Human coagulation factor vii polypeptides
|
US20090048440A1
(en)
|
2005-11-03 |
2009-02-19 |
Neose Technologies, Inc. |
Nucleotide Sugar Purification Using Membranes
|
US20080242607A1
(en)
|
2006-07-21 |
2008-10-02 |
Neose Technologies, Inc. |
Glycosylation of peptides via o-linked glycosylation sequences
|
US20100056428A1
(en)
|
2006-09-01 |
2010-03-04 |
Novo Nordisk Health Care Ag |
Modified proteins
|
US20100075375A1
(en)
|
2006-10-03 |
2010-03-25 |
Novo Nordisk A/S |
Methods for the purification of polypeptide conjugates
|
CN105838699A
(zh)
|
2006-12-15 |
2016-08-10 |
巴克斯艾尔塔公司 |
具有延长的体内半衰期的因子VIIa-聚唾液酸结合物
|
KR20100016160A
(ko)
|
2007-04-03 |
2010-02-12 |
바이오제너릭스 에이지 |
글리코페길화 g―csf를 이용하는 치료 방법
|
EP2147096B1
(de)
|
2007-04-13 |
2015-03-25 |
Catalyst Biosciences, Inc. |
Modifizierte Faktor-VII-Polypeptide und Verwendungen davon
|
MX2009013259A
(es)
|
2007-06-12 |
2010-01-25 |
Novo Nordisk As |
Proceso mejorado para la produccion de azucares de nucleotidos.
|
PT2574677T
(pt)
|
2007-12-27 |
2017-10-19 |
Baxalta Inc |
Processos para cultura de células
|
US20130189239A1
(en)
|
2008-02-27 |
2013-07-25 |
Novo Nordisk A/S |
Conjugated Factor VIII Molecules
|
TWI538916B
(zh)
|
2008-04-11 |
2016-06-21 |
介控生化科技公司 |
經修飾的因子vii多肽和其用途
|
DK2440239T3
(en)
|
2009-06-09 |
2017-10-16 |
Prolong Pharmaceuticals Llc |
HEMOGLOBIN FORMATIONS
|
FR2947181B1
(fr)
*
|
2009-06-26 |
2012-05-04 |
Lfb Biotechnologies |
Composition de facteur vii
|
US8642737B2
(en)
|
2010-07-26 |
2014-02-04 |
Baxter International Inc. |
Nucleophilic catalysts for oxime linkage
|
CA2769244A1
(en)
|
2009-07-27 |
2011-02-03 |
Lipoxen Technologies Limited |
Glycopolysialylation of non-blood coagulation proteins
|
JP5908401B2
(ja)
|
2009-07-27 |
2016-04-26 |
バクスター・インターナショナル・インコーポレイテッドBaxter International Incorp0Rated |
血液凝固タンパク質複合体
|
US8809501B2
(en)
|
2009-07-27 |
2014-08-19 |
Baxter International Inc. |
Nucleophilic catalysts for oxime linkage
|
CN104530182A
(zh)
|
2009-07-27 |
2015-04-22 |
利普森技术有限公司 |
非凝血蛋白的糖基多唾液酸化
|
EP2588499B1
(de)
|
2010-06-30 |
2020-04-08 |
Novo Nordisk A/S |
Zur bindung des gewebefaktor-gerinnungsweg-inhibitors fähige antikörper
|
SG191298A1
(en)
|
2010-12-22 |
2013-07-31 |
Baxter Int |
Materials and methods for conjugating a water soluble fatty acid derivative to a protein
|
KR20140012082A
(ko)
|
2011-03-02 |
2014-01-29 |
노보 노르디스크 에이/에스 |
활성화된 혈소판에서 tlt-1을 표적화하는 응고 인자
|
SI2717898T1
(sl)
|
2011-06-10 |
2019-07-31 |
Bioverativ Therapeutics Inc. |
Spojine prokoagulantov in metode za njihovo uporabo
|
EP2554161A1
(de)
|
2011-08-02 |
2013-02-06 |
LFB Biotechnologies |
Pharmazeutische Zusammensetzung enthaltend Faktor VII in Mizellen verkapselt
|
CN104717973A
(zh)
|
2012-10-10 |
2015-06-17 |
诺和诺德保健Ag(股份有限公司) |
因子vii多肽的液体药物组合物
|
US20150259665A1
(en)
|
2012-10-15 |
2015-09-17 |
Novo Nordisk Health Care Ag |
Factor vii conjugates
|
US20190015532A1
(en)
|
2016-01-15 |
2019-01-17 |
Rigshospitalet |
Quantitative pet imaging of tissue factor expression using 18f-labled active site inhibited factor vii
|
US20210069306A1
(en)
|
2019-08-15 |
2021-03-11 |
Catalyst Biosciences, Inc. |
Modified factor vii polypeptides for subcutaneous administration and on-demand treatment
|